We found that LIHC and PRAD patients with gains in MHC-I AgPPM genes showed more frequent EP300/CBP LOF (Fig. 5 D and E and SI Appendix, Table S1), suggesting a compensatory mechanism that allows cancers with elevated MHC-I AgPPM to evade immune recognition. Here, EP300 is linked to prostate adenocarcinoma.